15 results about "Glypican 3" patented technology

Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.

Provided herein are novel Glypican 3 (GPC3) antibodies or antigen binding fragments and GPC3 / CD3 bispecific antibodies. The present application also provides chimeric antigen receptors comprising the antibodies or antigen-binding fragments, related CAR-T cells, and preparation methods and uses of the same. The present application further provides pharmaceutical compositions comprising GPC3 antibodies or antigen binding fragments, related GPC3 / CD3 bispecific antibodies, related GPC3 CAR or CAR-T cells, and methods of treating cancer in a subject in need thereof by administering the Glypican 3 (GPC3) antibodies or antigen binding fragments, the bispecific antibodies, the chimeric antigen receptors, the CAR-T cells, or the pharmaceutical compositions. The cancers treated in accordance with the application include Glypican-3-positive cancers.

This new chimeric antigen receptor (CAR) T-cell therapy effectively treats cancer while minimizing the risk of dangerous inflammatory responses such as cytokine release syndrome. [Solution] An isolated nucleic acid sequence encoding a CAR, wherein the CAR includes an antigen-binding domain specific to glypican 3 (GPC3), the antigen-binding domain has an equilibrium dissociation constant (KD) of approximately 100 nanomoles (nM) or less, and the CAR construct provides an isolated nucleic acid sequence that does not induce cytokine production in GPC3-expressing cells.

Radiopharmaceuticals and conjugates targeting GPC3, as well as their compositions and uses, are provided herein. In one embodiment, a conjugate comprising a peptide having avidity to GPC3 and a metal chelating agent configured to bind to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. The conjugate described herein may further comprise a radionuclide. In one embodiment, a radiopharmaceutical comprising a peptide and a metal chelating agent binding to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. Methods for treating cancer by administering the radiopharmaceuticals, conjugates, and compositions thereof are further provided herein.

The present disclosure relates to compositions and methods for treating cancer using chimeric antigen receptor T cells that target glypican 3.

Described herein are anti-Glypican 3 (GPC3) antibodies and binding proteins including such binding domains, as well as nucleic acids encoding the same. The disclosure also features methods of using such antibodies, antigen-binding fragments, binding proteins, and nucleic acid to treat various diseases, such as cancer (e.g., HCC).

The disclosure provides amino acid sequences (e.g., antibodies) that can bind Glypican 3 Protein (GPC3). The disclosure relates to antigen binding fragments of GPC3 antibodies, conjugates, including immunoconjugates, of GPC3 antibodies, bispecific antibodies that include GPC3 antibodies, and related compositions and formulations. The disclosure also relates to methods for using the sequences, e.g., GPC3 antibodies and antigen-binding fragments thereof, in the treatment of GPC3-related diseases, disorders, and conditions including cell proliferative diseases such as cancer, and more particularly, liver cancer.

Described herein are antibody-drug conjugates (ADCs) comprising an antibody construct that binds to human glypican 3 (GPC3) conjugated to a camptothecin analog of formula (I). The ADCs are useful as therapeutic agents, particularly in the treatment of cancer.

The present invention relates to a glypican 3 single-domain antibody and its application. The amino acid sequence of CDR1 of the single-domain antibody includes the sequence shown in SEQ ID NO.1, the amino acid sequence of CDR2 includes the sequence shown in SEQ ID NO.2, and the amino acid sequence of CDR3 includes the sequence shown in SEQ ID NO.3. The present invention utilizes eukaryotically expressed GPC3 fusion protein to immunize camels, construct a phage display library, and screen to obtain glypican 3 single-domain antibodies with good specificity and affinity. At the same time, they have the characteristics of low molecular weight, which can effectively develop therapeutic drugs, engineered immune cells, and detection reagents.

Described herein are antibody-drug conjugates (ADCs) comprising an antibody construct that binds human glypican 3 (GPC3) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.

The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.

The application relates to the technical field of biological medicine, in particular to an anti-Glypican 3 antibody and application thereof, the anti-Glypican 3 antibody is coded as B6 and B51, the anti-Glypican 3 antibody comprises a heavy chain variable region, the heavy chain variable region of the anti-Glypican 3 antibody comprises CDR-H1 with an amino acid sequence as shown in SEQ ID No. 1, CDR-H2 as shown in SEQ ID No. 2 and CDR-H3 as shown in SEQ ID No. 3. The anti-Glypican 3 antibody has high affinity and specificity, can effectively target tumor antigen Glypican 3, a chimeric antigen receptor is prepared by using the anti-Glypican 3 antibody, and a chimeric antigen receptor cell is further prepared, the chimeric antigen receptor cell can efficiently kill tumor cells and has high specificity.

This disclosure provides anti-GPC3 antibodies, including murine antibodies, humanized antibodies, and those with further optimized CDR sequences. The newly disclosed antibodies exhibited higher cell-based binding efficiency than the leading anti-GPC3 antibody candidate under clinical development.

The invention provides application of a reagent for detecting phosphatidylinositol proteoglycan 3 in preparation of a product for diagnosing pleural pulmonary blastoma, and relates to the technical field of tumors. The research of the inventor finds that compared with healthy tissues or congenital cystic pulmonary disease tissues, the differential expression of the phosphatidylinositol proteoglycan 3 in pleural pulmonary blastoma tissues is up-regulated, and the expression level of the phosphatidylinositol proteoglycan 3 is related to the prognosis of pleural pulmonary blastoma, so that the phosphatidylinositol proteoglycan 3 can be used for treating the pleural pulmonary blastoma The phosphatidylinositol proteoglycan 3 can be used as a marker for diagnosis of pleural pulmonary blastoma, and has good sensitivity and specificity.